According to the results announced at the 2018 ASCO annual meeting, the CDK4/6 inhibitors pabociclib (Ibrance) and cetuximab (Erbitux) combined treatment of platinum-resistant and HPV-independent recurrent/metastatic head and neck The overall response rate for patients with squamous cell carcinoma (HNSCC) is 39%. In a non-randomized, 3-arm, phase II trial (NCT02101034), the results of a group of studies have a median progression-free survival (PFS) of 5.4 months, a median overall survival (OS) of 9.5 months, and a 1-year OS The rate is 35%.
In this study, 30 patients with HNSCC unrelated to HPV progressed after platinum-based therapy for relapsed/metastatic disease and participated in the trial. Patients who had previously received cetuximab for relapse and HPV-related oropharyngeal cancer were not eligible. Patients received palbociclib from day 1 to day 21, 125 mg daily; cetuximab, with a starting dose of 400 mg/m 2 and then 250 mg/m 2 per week for a period of 28 days until the disease progressed or withdrew the study. The researchers performed imaging examinations before treatment and after every 2 cycles.
L'âge médian des patients était de 67 ans et les sites tumoraux étaient la cavité buccale (47 %), le larynx (27 %) et l'oropharynx (13 %). 20 % des patients ont des métastases régionales locales, 27 % ont des métastases à distance et 53 % ont les deux. Quinze (50 %) patients ont reçu ≥ 2 traitements.
Sur les 28 patients évaluables, 11 (39%) avaient des réponses tumorales, dont 3 (11%) réponses complètes et 8 (29%) réponses partielles. Quatorze (50%) patients avaient une maladie stable, 3 (11%) patients avaient une progression et 70% avaient des lésions tumorales réduites.
Researcher Dr. Adkins said that Palbociclib and cetuximab have strong antitumor activity in platinum-resistant HPV-independent head and neck cancer, and biologically targeted therapy for HPV-independent head and neck cancer is an effective treatment strategy. . We look forward to the better results of the follow-up research.
